In The News
Hytera can’t dodge finding it committed ‘industrial theft’ of Motorola’s source code
Judge approves $31.5M settlement in junior doctors class action
ASIC claims crypto firm Binance denied protections to derivatives investors
Barrister who accepted briefs for appearances on same day referred to watchdog
CIMIC settles shareholder class action for $45.25M
Melbourne law firm argues 700 clients can’t sue for negligence in class action
Hall & Wilcox brings on Moray & Agnew public law specialist
Slashing funder’s stolen wages cut could deter public interest cases, court told
Law firm files first class action over Google’s ad tech dominance
Landmark $50M settlement over Meta’s Cambridge Analytica scandal
Please login to bookmarkClose

Novartis unit Sandoz AG has lost its bid to revoke Bayer’s patents for its top-selling blood clot drug Xarelto and has been barred from selling generic versions of the medication after a judge found the German pharma giant’s patents were valid.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au